241 related articles for article (PubMed ID: 24220695)
21. G-CSF and G-CSFR are highly expressed in human gastric and colon cancers and promote carcinoma cell proliferation and migration.
Morris KT; Khan H; Ahmad A; Weston LL; Nofchissey RA; Pinchuk IV; Beswick EJ
Br J Cancer; 2014 Mar; 110(5):1211-20. PubMed ID: 24448357
[TBL] [Abstract][Full Text] [Related]
22. Antiapoptotic effect of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and cyclic AMP on human neutrophils: protein synthesis-dependent and protein synthesis-independent mechanisms and the role of the Janus kinase-STAT pathway.
Sakamoto C; Suzuki K; Hato F; Akahori M; Hasegawa T; Hino M; Kitagawa S
Int J Hematol; 2003 Jan; 77(1):60-70. PubMed ID: 12568301
[TBL] [Abstract][Full Text] [Related]
23. Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
Westhoff GL; Chen Y; Teng NNH
Int J Gynecol Cancer; 2017 Oct; 27(8):1602-1609. PubMed ID: 28692634
[TBL] [Abstract][Full Text] [Related]
24. G-CSF and G-CSFR Modulate CD4 and CD8 T Cell Responses to Promote Colon Tumor Growth and Are Potential Therapeutic Targets.
Karagiannidis I; Jerman SJ; Jacenik D; Phinney BB; Yao R; Prossnitz ER; Beswick EJ
Front Immunol; 2020; 11():1885. PubMed ID: 33042110
[TBL] [Abstract][Full Text] [Related]
25. Granulocyte colony-stimulating factor receptor signals for beta1-integrin expression and adhesion in bladder cancer.
Chakraborty A; White SM; Lerner SP
Urology; 2004 Jan; 63(1):177-83. PubMed ID: 14751388
[TBL] [Abstract][Full Text] [Related]
26. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
Dos Santos Guimarães I; Ladislau-Magescky T; Tessarollo NG; Dos Santos DZ; Gimba ERP; Sternberg C; Silva IV; Rangel LBA
Pharmacol Rep; 2018 Jun; 70(3):409-417. PubMed ID: 29627688
[TBL] [Abstract][Full Text] [Related]
27. Sarcodon imbricatus polysaccharides improve mouse hematopoietic function after cyclophosphamide-induced damage via G-CSF mediated JAK2/STAT3 pathway.
Wang X; Chu Q; Jiang X; Yu Y; Wang L; Cui Y; Lu J; Teng L; Wang D
Cell Death Dis; 2018 May; 9(6):578. PubMed ID: 29784961
[TBL] [Abstract][Full Text] [Related]
28. The granulocyte colony-stimulating factor receptor supports erythroid differentiation in the absence of the erythropoietin receptor or Stat5.
Millot GA; Svinarchuk F; Lacout C; Vainchenker W; Dumenil D
Br J Haematol; 2001 Feb; 112(2):449-58. PubMed ID: 11167846
[TBL] [Abstract][Full Text] [Related]
29. Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.
Wei H; Hellström KE; Hellström I
Gynecol Oncol; 2012 Jun; 125(3):727-33. PubMed ID: 22430613
[TBL] [Abstract][Full Text] [Related]
30. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
31. Expression of granulocyte colony-stimulating factor receptor correlates with prognosis in oral and mesopharyngeal carcinoma.
Tsuzuki H; Fujieda S; Sunaga H; Noda I; Saito H
Cancer Res; 1998 Feb; 58(4):794-800. PubMed ID: 9485037
[TBL] [Abstract][Full Text] [Related]
32. Adipose Stromal Cells from Visceral and Subcutaneous Fat Facilitate Migration of Ovarian Cancer Cells via IL-6/JAK2/STAT3 Pathway.
Kim B; Kim HS; Kim S; Haegeman G; Tsang BK; Dhanasekaran DN; Song YS
Cancer Res Treat; 2017 Apr; 49(2):338-349. PubMed ID: 27456942
[TBL] [Abstract][Full Text] [Related]
33. Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment.
Bagnoli M; Balladore E; Luison E; Alberti P; Raspagliesi F; Marcomini B; Canevari S; Mezzanzanica D
Mol Cancer Ther; 2007 Feb; 6(2):762-72. PubMed ID: 17308072
[TBL] [Abstract][Full Text] [Related]
34. Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer.
Miow QH; Tan TZ; Ye J; Lau JA; Yokomizo T; Thiery JP; Mori S
Oncogene; 2015 Apr; 34(15):1899-907. PubMed ID: 24858042
[TBL] [Abstract][Full Text] [Related]
35. Granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor, PIXY-321, stem cell factor, interleukin-3, and interleukin-7: receptor binding and effects on clonogenic proliferation in acute lymphoblastic leukemia.
Drach D; Estrov Z; Zhao S; Drach J; Cork A; Collins D; Kantarjian H; Andreeff M
Leuk Lymphoma; 1994 Dec; 16(1-2):79-88. PubMed ID: 7535143
[TBL] [Abstract][Full Text] [Related]
36. Bivalent binding and signaling characteristics of Leridistim, a novel chimeric dual agonist of interleukin-3 and granulocyte colony-stimulating factor receptors.
Monahan JB; Hood WF; Welply JK; Shieh JJ; Polazzi JO; Li X
Exp Hematol; 2001 Apr; 29(4):416-24. PubMed ID: 11301181
[TBL] [Abstract][Full Text] [Related]
37. HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer.
Wang Y; Wang H; Song T; Zou Y; Jiang J; Fang L; Li P
Mol Med Rep; 2015 Aug; 12(2):2211-6. PubMed ID: 25824616
[TBL] [Abstract][Full Text] [Related]
38. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
[TBL] [Abstract][Full Text] [Related]
39. Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429.
Guo Q; Lu L; Liao Y; Wang X; Zhang Y; Liu Y; Huang S; Sun H; Li Z; Zhao L
Cell Death Dis; 2018 Jan; 8(1):e3178. PubMed ID: 29324735
[TBL] [Abstract][Full Text] [Related]
40. SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth.
Mills KA; Roach ST; Quinn JM; Guo L; Beck HM; Lomonosova E; Ilivicky AR; Starks CM; Lawrence JA; Hagemann AR; McCourt C; Thaker PH; Powell MA; Mutch DG; Fuh KC
Gynecol Oncol; 2018 Nov; 151(2):337-344. PubMed ID: 30190114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
